Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells. Source
No articles found.
Helen of Troy Limited (NASDAQ: HELE) is a leading global consumer products company...
Helen of Troy Limited (NASDAQ: HELE) is a leadi...
Acasti is a biopharmaceutical innovator focused on the research, development and c...
Acasti is a biopharmaceutical innovator focused...
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...
Evelo Biosciences, Inc. is a clinical stage bio...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâ...
Nemucore Medical Innovations is here to bring y...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...
20/20 GeneSystems, Inc. an early stage digital ...
Join the National Investor Network and get the latest information with your interests in mind.